Which has grown faster, CSBR or SPRO?

Over the past five years, SPRO grew revenue faster — CSBR at a 7.25% CAGR versus SPRO at 22.93%.

Is CSBR or SPRO more profitable?

SPRO runs the higher net margin — CSBR at -1.87% versus SPRO at 17.18%.

How have CSBR and SPRO total returns compared?

Over the past 5 years, CSBR delivered -13.07% and SPRO delivered -42.70% annualized total return. Past performance doesn't predict future results.

Champions Oncology, Inc. (CSBR) vs Spero Therapeutics, Inc. (SPRO)

A side-by-side comparison of Champions Oncology, Inc. and Spero Therapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

CSBR

Champions Oncology, Inc.

$70M

$5.01HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT

SPRO

Spero Therapeutics, Inc.

$69M

$1.19HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT

Total return — CSBR vs SPRO

growth of $100 · dividends reinvested · last 9y

CSBR +55.3% (+5.0%/yr)SPRO -89.9% (-22.5%/yr)CSBR compounded faster over this window

Log scale — wide-divergence pair

CSBR SPRO

CSBR vs SPRO: by the numbers

•CSBR is the larger company ($70M vs $69M market cap).
•SPRO is profitable (17.18% net margin) while CSBR runs a net loss (-1.87%).
•SPRO grew revenue faster over the past five years (22.93% vs 7.25% CAGR).

Metrics side by side

Valuation

Metric	CSBR	SPRO
P/E ratio	N/A	10.82
Forward P/E	50.10	N/A
P/S ratio	1.15	1.60
P/B ratio	17.88	1.56
EV / EBITDA	261.92	3.35
FCF yield	N/A	28.42%

Profitability

Metric	CSBR	SPRO
Gross margin	49.30%	100.00%
Operating margin	-1.72%	-0.04%
Net margin	-1.87%	17.18%
ROE	-29.15%	16.70%
ROIC	-6.75%	13.12%

Growth (annualized)

Metric	CSBR	SPRO
Revenue CAGR (5Y)	7.25%	22.93%
Total return CAGR (5Y)	-13.07%	-42.70%

Frequently asked

Which has grown faster, CSBR or SPRO?: Over the past five years, SPRO grew revenue faster — CSBR at a 7.25% CAGR versus SPRO at 22.93%.
Is CSBR or SPRO more profitable?: SPRO runs the higher net margin — CSBR at -1.87% versus SPRO at 17.18%.
How have CSBR and SPRO total returns compared?: Over the past 5 years, CSBR delivered -13.07% and SPRO delivered -42.70% annualized total return. Past performance doesn't predict future results.

Go deeper

Full CSBR analysis Full SPRO analysis Interactive comparison tool

Dig into the metrics

Spero Therapeutics P/E ratio Champions Oncology ROE Spero Therapeutics ROE Champions Oncology operating margin Spero Therapeutics operating margin Champions Oncology revenue growth Spero Therapeutics revenue growth Champions Oncology free cash flow Spero Therapeutics free cash flow

Champions Oncology & Spero Therapeutics appear in these rankings

Fastest Revenue Growth Stocks Highest FCF Yield Stocks Lowest P/E Ratio Stocks

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.